EP2951171A1 — Radiolabeled quinazoline derivatives
Assigned to Boehringer Ingelheim International GmbH · Expires 2015-12-09 · 10y expired
What this patent protects
Novel radiotracer for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging are described. Specifically, the invention relates to 18 F-labeled afatinib suitable as a PET or SPECT tracer for imaging epidermal growth factor receptor (EGFR…
USPTO Abstract
Novel radiotracer for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging are described. Specifically, the invention relates to 18 F-labeled afatinib suitable as a PET or SPECT tracer for imaging epidermal growth factor receptor (EGFR, erbB1) and human epidermal growth factor receptor 2 (Her2, erbB2), to a precursor compound for use in its synthesis, to methods for the preparation 18 F-iabeled afatinib, as well as to the use thereof in in vivo diagnosis, tumor imaging or patient stratification on the basis of mutational status of EGFR (erbB1) and Her2 (erbB2).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.